v3.26.1
Consolidated Statements of Income and Comprehensive Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Revenues $ 47,943 $ 48,561 $ 95,388 $ 99,307
Cost of products sold 34,077 36,960 71,412 74,961
Gross profit 13,866 11,601 23,976 24,346
Operating expenses:        
Research and development 3,225 2,318 6,186 4,722
Selling, general and administrative 7,204 7,027 14,568 13,969
Total operating expenses 10,429 9,345 20,754 18,691
Operating income 3,437 2,256 3,222 5,655
Other expense (income):        
Interest and financing expense 839 992 1,707 2,024
Miscellaneous (income) expense (388) 151 (808) 72
Total other expense 451 1,143 899 2,096
Income before income taxes 2,986 1,113 2,323 3,559
Income tax provision 468 243 276 810
Net income 2,518 870 2,047 2,749
Net (loss) income attributable to non-controlling interest (25) (9) (45) 5
Net income attributable to Ultralife Corporation        
Net income attributable to Ultralife Corporation 2,543 879 2,092 2,744
Foreign currency translation adjustments 212 875 295 1,186
Comprehensive income attributable to Ultralife Corporation $ 2,755 $ 1,754 $ 2,387 $ 3,930
Net income per share attributable to Ultralife common stockholders – basic (in dollars per share) $ 15 $ 5 $ 13 $ 17
Net income per share attributable to Ultralife common stockholders – diluted (in dollars per share) $ 15 $ 5 $ 13 $ 17
Weighted average shares outstanding – basic (in shares) 16,659 16,635 16,658 16,634
Potential common shares (in shares) 55 21 45 37
Weighted average shares outstanding - diluted (in shares) 16,714 16,656 16,703 16,671